Drugs / CD19 CAR-T cells
last change Jul 2026 re-read 2 minutes ago

CD19 CAR-T cells

Cell therapy targets CD19, CD22 via depletion

Developed for
B-cell acute lymphoblastic leukemia · systemic lupus erythematosus · acute lymphoblastic leukemia · B-cell non-Hodgkin lymphoma · diffuse large B-cell lymphoma · mantle cell lymphoma · adult acute lymphoblastic leukemia · autoimmune disease
+15 more · B-cell adult acute lymphocytic leukemia · B-cell chronic lymphocytic leukemia · B-cell neoplasm · follicular lymphoma · precursor B-cell acute lymphoblastic leukemia · Burkitt lymphoma · childhood acute lymphoblastic leukemia · chronic lymphocytic leukemia/small lymphocytic lymphoma · large B-cell lymphoma · leukemia · lymphoma · myasthenia gravis · non-Hodgkin lymphoma · primary central nervous system lymphoma · refractory plasma cell neoplasm
Investigated by
Beijing GoBroad Hospital · Zhejiang University · Chongqing Precision Biotech Co., Ltd · Institute of Hematology & Blood Diseases Hospital, China · Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd · The First Affiliated Hospital of Soochow University
+44 more · Yake Biotechnology Ltd. · Juventas Cell Therapy Ltd. · National University of Malaysia · The General Hospital of Western Theater Command · Xuzhou Medical University · Avalon GloboCare Corp. · Belarusian Research Center for Pediatric Oncology, Hematology and Immunology · Bioceltech Therapeutics, Ltd. · CSPC Pharmaceutical Group Limited · Central People's Hospital of Zhanjiang · Chengdu Ucello Biotechnology Co., Ltd. · China Immunotech (Beijing) Biotechnology Co., Ltd. · City of Hope Medical Center · First Affiliated Hospital of Guangxi Medical University · First Hospital of China Medical University · Gaia Science · Hebei Senlang Biotechnology Inc., Ltd. · Hebei Yanda Ludaopei Hospital · Henan Province Engineering Technology Research Center of Immunological Precision Medicine and Artificial Intelligence Application, Luoyang, China · Hrain Biotechnology Co., Ltd. · Memorial Sloan Kettering Cancer Center · National Cancer Institute (NCI) · PersonGen BioTherapeutics (Suzhou) Co., Ltd. · Plutonet Sdn Bhd · Ruijin Hospital · Shanghai Changzheng Hospital · Shanghai Jiao Tong University School of Medicine · Shanghai Liquan Hospital · Shanghai Longyao Biotechnology Inc., Ltd. · Sheba Medical Center · ShenZhen Cell Valley · The Affiliated Hospital of Xuzhou Medical University · The Children's Hospital of Zhejiang University School of Medicine · The First Affiliated Hospital of Nanchang University · The First Affiliated Hospital of Zhengzhou University · The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine · Third Military Medical University · Tianjin Mycure Medical Technology Co., Ltd · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · University College, London · University Hospital Heidelberg · Xinqiao Hospital of Chongqing · Zhaxin Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai · Zhujiang Hospital

Trials 40 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 02 trials
Phase 0 NCT07277504 Dec 2025 → Dec 2030 expected B-cell adult acute lymphocytic leukemia The General Hospital of Western Theater Command Not yet recruiting No outcome recorded
Phase 0 NCT05239676 Feb 2022 → Dec 2024 lymphoma Zhejiang University Unknown No outcome recorded
Phase 115 trials
Phase 1 NCT06326008 Mar → Jun 2026 overdue B-cell acute lymphoblastic leukemia Beijing GoBroad Hospital Recruiting No outcome recorded
Phase 1 NCT07331467 Jan → Jul 2026 overdue systemic lupus erythematosus Chongqing Precision Biotech Co., Ltd Recruiting No outcome recorded
Phase 1 NCT07233642 Nov 2025 → May 2026 overdue systemic lupus erythematosus The Children's Hospital of Zhejiang University School of Medicine Recruiting No outcome recorded
Phase 1 NCT06710717 Jan 2025 → Dec 2028 expected systemic lupus erythematosus National University of Malaysia Recruiting No outcome recorded
Phase 1 NCT05828225 Apr 2023 → Apr 2026 myasthenia gravis Zhejiang University Unknown No outcome recorded
Phase 1 NCT04556266 Jul 2021 → Mar 2022 B-cell non-Hodgkin lymphoma, leukemia Memorial Sloan Kettering Cancer Center Withdrawn No outcome recorded
Phase 1 NCT04443829 Mar 2021 → Dec 2024 overdue primary central nervous system lymphoma University College, London Active not recruiting No outcome recorded
Phase 1 NCT05333302 Oct 2020 → Dec 2024 overdue B-cell acute lymphoblastic leukemia Belarusian Research Center for Pediatric Oncology, Hematology and Immunology Recruiting No outcome recorded
Phase 1 NCT04194931 Dec 2019 → Dec 2020 refractory plasma cell neoplasm The First Affiliated Hospital of Nanchang University Unknown No outcome recorded
Phase 1 NCT03952923 Aug 2019 → Jan 2021 B-cell neoplasm Hebei Yanda Ludaopei Hospital Completed No outcome recorded
Phase 1/214 trials
Phase 1/2 NCT07161193 Sep 2025 → Aug 2027 expected autoimmune disease Hebei Senlang Biotechnology Inc., Ltd. Not yet recruiting No outcome recorded
Phase 1/2 NCT07072494 Jul 2025 → Mar 2027 expected acute lymphoblastic leukemia Zhujiang Hospital Recruiting No outcome recorded
Phase 1/2 NCT06688799 Nov 2024 → Mar 2026 overdue autoimmune disease Beijing GoBroad Hospital Recruiting No outcome recorded
Phase 1/2 NCT06585514 Oct 2024 → Sep 2026 expected lupus nephritis, systemic lupus erythematosus Beijing GoBroad Hospital Recruiting No outcome recorded
Phase 1/2 NCT06464185 Apr 2024 → Mar 2026 overdue B-cell non-Hodgkin lymphoma Institute of Hematology & Blood Diseases Hospital, China Active not recruiting No outcome recorded
Phase 1/2 NCT04271800 Dec 2019 → Dec 2023 B-cell chronic lymphocytic leukemia Chongqing Precision Biotech Co., Ltd Unknown No outcome recorded
Phase 1/2 NCT04271410 Jun 2019 → Dec 2023 B-cell chronic lymphocytic leukemia, diffuse large B-cell lymphoma Chongqing Precision Biotech Co., Ltd Unknown No outcome recorded
Phase 1/2 NCT03676504 Sep 2018 → Dec 2026 expected adult acute lymphoblastic leukemia, childhood acute lymphoblastic leukemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, diffuse large B-cell lymphoma +2 University Hospital Heidelberg Recruiting No outcome recorded
Phase 1/2 NCT05381662 Aug 2018 → Aug 2024 acute lymphoblastic leukemia Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd Unknown No outcome recorded
Phase 1/2 NCT03275493 Jul 2017 → Dec 2024 B-cell acute lymphoblastic leukemia Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd Unknown No outcome recorded
Phase 25 trials
Phase 2 NCT07252336 Nov 2025 → Nov 2027 expected Zhejiang University Recruiting No outcome recorded
Phase 2 NCT06608342 Jun 2024 → May 2026 overdue adult acute lymphoblastic leukemia Institute of Hematology & Blood Diseases Hospital, China Recruiting No outcome recorded
Phase 2 NCT05755828 Dec 2022 → Dec 2024 B-cell non-Hodgkin lymphoma The Affiliated Hospital of Xuzhou Medical University Unknown No outcome recorded
Phase 2 NCT06220097 Feb 2022 → Aug 2024 overdue B-cell acute lymphoblastic leukemia Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Active not recruiting No outcome recorded
Phase 2 NCT04661020 Dec 2020 → Dec 2026 expected large B-cell lymphoma Zhejiang University Recruiting No outcome recorded
Phase 2/31 trial
Phase 2/3 NCT03937544 Mar 2019 → Jan 2027 expected B-cell acute lymphoblastic leukemia, precursor B-cell acute lymphoblastic leukemia National University of Malaysia Recruiting No outcome recorded
Phase not applicable3 trials
NCT07193667 Oct 2025 → Sep 2027 expected ShenZhen Cell Valley Recruiting No outcome recorded
NCT06343090 Apr 2024 → Dec 2042 expected B-cell acute lymphoblastic leukemia Beijing GoBroad Hospital Recruiting No outcome recorded
NCT04237428 May → Jun 2019 non-Hodgkin lymphoma PersonGen BioTherapeutics (Suzhou) Co., Ltd. Unknown No outcome recorded

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 41 sources stand behind the page.

FieldValueCited text
Known as CD19 CAR-T Cells “CD3-CD20 bispecific antibody-based therapy in combination with CD19-CAR-T cells for the treatment of relapsed and refractory B-cell Non-Hodgkin's (B-NHL) lymphoma.” NCT06464185
39

“Engineered TCM-derived CD19 CAR T cells were infused 2 days after HSCT at doses of 25 to 200 × 10(6) in a single infusion.” PMID 27118452 Apr 2016

“Peripheral blood mononuclear cells for the production of CD19 CAR T cells and CD22 CAR T cells are collected from donors.” NCT06326008

CD19 CAR-T cells were prepared from peripheral lymphocytes of NHL patients with PR after 3 to 4 courses of chemotherapy” NCT05755828

“modified T cells' (or CD19 chimeric antigen T cells, also called CD19 CAR T cells) that target the B cell marker” NCT04556266

“Autologous CD19-CAR T cells were transfused +7 days after autologous hematopoietic stem cell transplantation” NCT06608342

“Autologous CD19 CAR-T cells and CD20 CAR-T cells with average 1-5\*10\^6 cells/kg body weight,separately.” NCT03207178

“Patients with Refractory Autoimmune Diseases will receive CD19 CAR T cells.” NCT07161193

“Murine-derived CD19 CAR T cells” NCT06343090

NCT06220097

NCT03275493

NCT04194931

NCT04271410

NCT06688799

NCT04271800

NCT07331467

NCT07193667

NCT03952923

NCT03676504

NCT04443829

NCT03671460

NCT06585514

NCT03064269

NCT05239676

NCT02772198

NCT06710717

NCT05333302

NCT07277504

NCT07233642

NCT02652910

NCT04661020

NCT03298828

NCT07252336

NCT03937544

NCT03574168

NCT02975687

NCT05828225

NCT05381662

NCT07072494

NCT04237428

Known as CD19 chimeric antigen T cells “modified T cells' (or CD19 chimeric antigen T cells, also called CD19 CAR T cells) that target the B cell marker” NCT04556266
Action Deplete “CAR-Ts with shRNA-IL-6 gene knockdown migrated into the CNS, eradicated leukemic cells” PMID 32745961 Jul 2020
Modality Cell therapy “using ex vivo-expanded autologous central memory-enriched T cells (TCM) transduced with lentivirus expressing CD19-specific chimeric antigen receptors (CARs).” PMID 27118452 Apr 2016
Route Intravenous “CD19 CAR T cells will be administered by i.v. injection” NCT02975687
Target CD19 CD19-specific CARs” NCT02652910